Why These 24 Stocks Are Skyrocketing

Page 17 of 23

7. Aligos Therapeutics, Inc. (NASDAQ:ALGS)

Q4 Returns as of December 31, 2024: 360%

ALGS registered a 360% increase in its stock price during the fourth quarter of 2024, going from $8.66 on September 30 to $39.84 apiece on December 31, 2024.

The surge in ALGS’ stock price underscores investor optimism and a positive investor outlook. Its growing popularity can be attributed to its expanding product pipeline and positive data from clinical trials.

Aligos Therapeutics (ALGS) boasts an estimated opportunity worth $6.2 billion by 2031 as the number of patients with chronic hepatitis eyes an upward trajectory. So far, its trials have yielded positive results, boosting the company’s current and future position.

Page 17 of 23